上市两个月,礼来将匹妥布替尼片“外包”给信达生物

中新经纬
16 Dec 2024

中新经纬12月16日电 (王玉玲)16日,跨国医药企业礼来制药(下称礼来)宣布,与信达生物制药集团(下称信达生物)达成合作协议,礼来将捷帕力(匹妥布替尼100毫克和50毫克片剂)(下称匹妥布替尼)在中国大陆的进口、销售、推广和分销工作授权给信达生物,礼来将负责匹妥布替尼的研发和上市后医学事务相关工作。匹妥布替尼10月经中国国家药品监督管理局(NMPA)获批在中国上市。刚上市不到两个月,礼来就将...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10